News & Updates

Heart diseases, chronic obstructive pulmonary disease (COPD), concomitant cancers, and other co-occurring diseases elevate the risk of death in patients with nonmuscular invasive bladder cancer (NMIBC), nonmetastatic muscle invasive bladder cancer (non-MMIBC), and metastatic bladder cancer (MBC), according to a recent study.

In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).

The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.

Cancer patients who experience treatment delays due to the COVID-19 pandemic restrictions may be vulnerable to psychological distress, reports a recent China study. Effective communication from doctors and other cancer care professionals may help mitigate this effect.

Use of dostarlimab, a single-agent programmed death 1 (PD-1) monoclonal antibody, appears to have successfully cured mismatch repair-deficient, locally advanced rectal cancer, reports a recent study.